A new publication from CorriXR Therapeutics, an oncology focused biotherapeutics company developing genetic medicines to overcome drug resistance in solid tumors, shows that its novel CRISPR-directed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback